格隆汇3月27日丨心通医疗-B(02160.HK)公布年度业绩,截至2024年12月31日止年度,集团收入为人民币3.616亿元,相比于截至2023年12月31日止年度的人民币3.362亿元增加了7.5%,主要是由于报告期内,VitaFlow Liberty®及Alwide®Plus在全球商业化的持续推进,促进了TAVI产品的海外收入高速增长。此外,于报告期内,我们的附属公司上海佐心自主研发的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.